USPTO BCP Meetings

BCP meetings are part of a long-standing partnership between the USPTO and our valued stakeholders that works to improve the quality of our products and services. The meeting’s discussion topics include: Prior art in a litigation world; After final practice and request for continued examination; Using Food and Drug Administration and National Institutes of Health databases to search drugs, formulations and their methods of use; Enablement in the chemical arts

BCP meetings are part of a long-standing partnership between the USPTO and our valued stakeholders that works to improve the quality of our products and services. The meeting’s discussion topics include:Prior art in a litigation world, After final practice and request for continued examination, Using Food and Drug Administration and National Institutes of Health databases to search drugs, formulations and their methods of use, and Enablement in the chemical arts.

BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders that works to improve the quality of the agency’s products and services. The meeting’s discussion topics include: Summary of Amgen v. Sanofi; 35 U.S.C. 112(a); Reexamination; Best practices to help growth stage companies build their IP portfolio; Patent Center and DOCX; Common sequence compliance errors.

BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders. The partnership works to improve the quality of the agency’s products and services.

Share your insights and experiences to improve patent prosecution in biotechnology areas at the next United States Patent and Trademark Office's (USPTO) Biotechnology, Chemical, and Pharmaceutical Customer Partnership (BCP) meeting.

BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders. The partnership works to improve the quality of the agency’s products and services.

BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders that works to improve the quality the agency’s products and services.

All stakeholders are invited to the USPTO's Biotechnology, Chemical and Pharmaceutical Partnership (BCP) Meeting to share insights and experiences to improve patent prosecution in these areas. The meeting will be held at the USPTO headquarters in Alexandria, Virginia, and online. Participants will be able to speak with agency experts either in person or via webcast from all locations.

Summary: BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders that works to improve the quality of the agency’s products and services. The next meeting’s discussion topics include: Subject Matter Eligibility (35 U.S.C. §101) 2019 Patent Subject Matter Eligibility Guidance Update; Stakeholder Perspectives on 101; Subject Matter Eligibility Discussion Panel; Written Description TC1600 Quality Initiatives and Plans; Global Dossier; Cooperative Patent Classification in Biotech.

​USPTO September 24, 2018 BCP meeting presentation by Abraham Amjad, SPE and Shubo (Joe) Zhou, SPE TC1600 on "Requirements for Information Under 37 CFR 1.105 and Responses to Said Requirements."

Due to inclement weather in the Washington D.C. area, the USPTO BCP conference planned for March 22, 2018 was cancelled.